SANTA BARBARA, CALIFORNIA (PRWEB) June 09, 2014
USDM Life Sciences, a leading global regulatory consulting firm in the life sciences industry, is pleased to announce Jay Crowley, Vice President of UDI Solutions and Services, will be part of a panel discussion about medical device labeling at the Drug Information Association (DIA) Annual Meeting in San Diego, CA. Crowley is scheduled to speak at 9:00 a.m. on Thursday, June 19.
Crowley will address the challenges and opportunities of global UDI implementation. The forum will also focus on how to create company core labeling for devices, the implementation process and tracking of core labeling changes and how to create optimal global patient labeling.
“I continue to enjoy working with companies to address the challenges and opportunities of UDI implementation – to not only address UDI compliance but to derive value for all stakeholders,” said Crowley. “I want to make sure organizations are taking advantage of all the benefits of the UDI system.”
As Vice President of UDI Solutions and Services at USDM Life Sciences, Crowley helps medical device manufacturers achieve regulatory compliance as well as internal benefits and competitive advantage with UDI implementation. The FDA UDI Final Rule requires that most medical devices distributed in the United States carry a Unique Device Identifier, or UDI.
Crowley held various positions over nearly 27 years at the FDA. Most recently, he was Senior Advisor for Patient Safety, in the FDA’s Center for Devices and Radiological Health. Crowley had primary responsibility for the development and implementation of the FDA’s UDI system.
About USDM Life Sciences:
USDM Life Sciences is a leading global regulatory consulting firm providing compliance, validation, qualification, quality, auditing and information technology services via project teams and staff augmentation to our clients in the medical device, biotechnology, biologics, diagnostics and pharmaceutical industries. USDM Life Sciences has more than 14 years of experience supplying our clients in the life science industry with compliance services during each phase of their drug and product development cycle while partnering with best of breed organizations to help companies simplify, unify and optimize their business and compliance objectives. For more information, please visit http://www.usdm.com.